# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Lemon et al.	)	Group Art Unit:	1648
		)		
Serial No.:	10/580,979	)	Examiner:	Bao Q. Li
Confirmation	No.: 9290	)		
		)		
371(c) filing date: April 9, 2007		)		
	·	)		
For:	REPLICATION COMPETENT HEPATITIS C VIRUS AND			
	METHODS OF USE			

#### COMMUNICATION and AMENDMENT REGARDING SEQUENCE LISTING

## Mail Stop Sequence

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This communication is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure dated March 9, 2009. Applicants request that the application be amended to enter the Sequence Listing. The Sequence Listing does not contain any new matter.

In accordance with 37 C.F.R. §1.821 et seq., a computer readable form (CRF) of the Sequence Listing, which is in compliance with 37 C.F.R. §1.824(a)(2)-(6) and (b), for the above-identified application is submitted herewith.

The Sequence Listing, in electronic form, which is in compliance with 37 C.F.R. §1.824(a)(2)-(6) and (b), for the above-identified application is submitted herewith. Applicants respectfully submit that the electronic text file will serve as both the paper copy required by 37 CFR 1.821(c) and the CRF required by 37 CFR 1.821(e). Thus a statement under 37 CFR 1.821(f) (indicating that the paper copy and CRF copy of the sequence listing are identical) is unnecessary.

## Communication and Amendment Re: Sequence Listing

Applicant(s): Lemon et al. Serial No.: 10/580,979 Confirmation No.: 9290 Filed: April 9, 2007

For: REPLICATION COMPETENT HEPATITIS C VIRUS AND METHODS OF USE

Applicant(s) believe there is no fee due at this time. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

The application should now be in condition for examination. Please direct any inquiries to the undersigned attorney.

#### CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper, as described hereinabove, is being transmitted via the U.S. Patent and Trademark Office electronic filing system in accordance with 37 CFR §1.6(a)(4) to the Patent and Trademark Office addressed to: Mail Stop Sequence, Commissioner for Patents, P.Q. Box 1450, Alexandria, VA 22313-1450, on this April, 2009.

By: Name: Divi MONOT

Date

Respectfully submitted

By

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220 Facsimile: (612)305-1228 **Customer Number 26813** 

David L. Provence Reg. No. 43,022

Direct Dial (612)305-1005